Boston Scientific (NYSE:BSX) today posted 1st-quarter sales that topped expectations on Wall Street, but share prices slid anyway in pre-market trading as investors reacted to a 1¢ miss on earnings. The Marlborough, Mass.-based company reported profits of $290 million, or 21¢ per share, on sales of $2.16 billion for the 3 months ended March 31, for a bottom-line […]
MassDevice Earnings Roundup
New GSK chief exec: Fewer, more focused drug programs as generic competition looms
In her 1st comments since taking the helm on April 1st, GlaxoSmithKline‘s (NYSE:GSK) new chief executive Emma Walmsley said that her priority is the company’s pharmaceuticals unit, where she wants to lead fewer but bigger new drug launches. “We’d like to have probably fewer and more focused priorities, to have bigger launches,” she told reporters, according […]
United Therapeutics misses estimates for Q1 rev, earnings
Shares in United Therapeutics (NSDQ:UTHR) fell today after the biotech company missed expectations on Wall Street with its 1st quarter results. The Silver Spring, Md.-based company posted profits of $178.6 million, or $3.89 per share, on sales of $370.5 million for the 3 months ended March 31, for bottom-line loss of -24% on sales growth of 0.4% compared […]
Novartis misses on rev, tops sales estimates in Q1
Shares in Novartis (NYSE:NVS) rose today after the pharmaceutical company met expectations on Wall Street with its 1st quarter earnings, but missed on sales largely thanks to growing pressure from generics to the company’s top-selling chemotherapy, Gleevec. The company posted profits of $1.92 billion, or 22¢ per share, on sales of $11.53 billion for the 3 months […]
3M posts Street-beating Q1 results, updates full-year guidance
Shares in 3M (NYSE:MMM) rose today after the company met expectations on Wall Street with its 1st quarter results. The St. Paul, Minn.-based company posted profits of $1.32 billion, or $2.16 per share, on sales of $7.69 billion for the 3 months ended March 31, for bottom-line growth of 3.1% on sales growth of 3.8% compared with […]
Eli Lilly’s diabetes drugs boost Q1 revenue, earnings
Shares in Eli Lilly (NYSE:LLY) fell slightly today as the company met expectations on Wall Street with its 1st quarter financial results. The company has faced its share of issues in the last year – Lilly took a $150 million hit in November after its Alzheimer’s drug failed in a clinical trial and this month, the […]
Milestone Scientific lands marketing clearance in Saudi Arabia, Australia
Milestone Scientific (NYSE:MLSS) shares rose today after the company said it won marketing clearance in Saudi Arabia, weeks after winning a regulatory nod in Australia for its epidural and intra-articular instruments. The company’s CompuFlo Epidural instrument uses dynamic pressure sensing to help anesthesiologists correctly identify the epidural space and significantly reduce complications, according to Milestone. The […]
Dicerna raises $70m, reels in losses for Q4
Shares in Dicerna Pharmaceuticals (NSDQ:DRNA) jumped 19% to $3.20 apiece today after the company said it raised $70 million in a convertible stock purchase deal and posted its 4th quarter results. Bain Capital Life Sciences led the investment round, joined by EcoR1 Capital, Cormorant Asset Management, RA Capital, Domain Associates, Skyline Ventures and others. Bain […]
SteadyMed reels in losses with Q4 earnings
Shares in SteadyMed (NSDQ:STDY) rose yesterday after the pharmaceutical company reported its 4th quarter results. The San Ramon, Calif.-based company posted losses of -$2.4 million, or -12¢ per share, on sales of $400,000 for the 3 months ended Dec. 31, for bottom-line growth of 63.1% on sales loss of -25.6% compared with the same period last year. […]
Sanofi gains on Q4 results; a look at some of the top drug-delivery earners in 2016
Shares in Sanofi (NYSE:SNY) have gained 11% to $44.58 apiece since the company released its 4th-quarter and full year 2016 financial results in February. The French company posted profits of $731.5 million on sales of $8.21 billion for the 3 months ended Dec. 31, for bottom-line growth of 136.5% on sales growth of 3.3% compared with […]
